The Clinical Trial Has No AI Rulebook

The Gap Nobody Is Regulating

Most of the AI governance conversation in life sciences runs through the drug or the device. FDA has a pathway for AI-enabled Software as a Medical Device, complete with predetermined change control plans for models that evolve after clearance, and it keeps expanding the list of authorized products under that framework, as BioSpace and Fact.MR both track. NGeneBio’s recent CE-IVDR certification for a hereditary cancer diagnostic panel shows the same logic working on the diagnostics side. If the AI is the product, there is a route to market, however demanding.

The AI running the trial itself is a different story. Sponsors and CROs are using AI for site selection, patient matching, point-of-care data capture, and monitoring, none of which is the thing FDA or EMA is reviewing. It is the infrastructure around the review. A Bourne Partners analysis found that the lack of regulatory clarity for AI use in clinical trial conduct is a leading barrier to adoption among sponsors and contractors, with Bourne’s head of research telling BioXconomy that today there is limited explicit regulation of AI in this part of the pipeline. There is no equivalent of predetermined change control plans for the AI that decides which patients get recruited or which data points get flagged as anomalies.

That gap has real consequences downstream. Richard Graham at TruTechnologies points out that AI is generating drug candidates faster than ever, but no AI-discovered drug has actually cleared clinical trials, and the reason is not the molecule. It is execution: poor point-of-care data, weak trial infrastructure, and governance that has not caught up with the tools sponsors are already deploying, as he describes to Applied Clinical Trials. SynBioBeta’s coverage of generative biology makes the same point from the discovery side: AI can pick targets and design molecules, but it cannot fix weak clinical execution or a trial built for the wrong patients, per SynBioBeta.

What This Means for Compliance Leaders

Waiting for FDA or EMA to issue trial-operations-specific AI guidance is not a strategy, because Good Clinical Practice, 21 CFR Part 11, and existing data integrity rules already apply to any system that touches trial data, AI or not. The absence of AI-specific rules does not create a compliance vacuum. It shifts the burden onto sponsors to demonstrate, unprompted, that their AI tools for recruitment, monitoring, and data capture meet the same validation, audit trail, and traceability standards inspectors already expect.

The practical move is to treat trial-operations AI as a quality system problem now, using a framework like ISO 42001 to document model validation, change control, and human oversight before a regulator asks. Sponsors who wait for explicit AI rules for trial conduct will find GCP inspectors asking the same data integrity questions they always have, just about a system nobody validated in advance.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The core argument—that AI in trial operations faces a regulatory gap distinct from AI-as-product—is coherent and supported, but the claim that ‘no AI-discovered drug has actually cleared clinical tria
Source & Claim Verification	Qwen · local	cleared. Most factual claims are supported by citations, but a few lines lack direct references, such as the statement about the gap having real consequences downstream.
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately identifies the regulatory gap for AI in clinical trial operations but understates the direct applicability of ISO 42001, EU AI Act, and GCP requirements to these use cases.
Technical Accuracy	Llama	cleared. The article accurately describes the current regulatory landscape for AI in clinical trials, highlighting the gap in explicit guidance and the need for sponsors to apply existing quality system standa
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively identifies a regulatory gap and counters potential vendor hype by emphasizing existing compliance obligations and the need for proactive validation.
Novelty & Non-Duplication	Grok	held. Core claim that trial-operations AI lacks explicit rules while product/SaMD AI has pathways is already on the wire (BioXconomy/Bourne, Applied Clinical Trials), so this is synthesis and compliance ref
Validation	DeepSeek	cleared. The central claim that there is a significant regulatory gap for AI used in clinical trial operations, as opposed to AI as a medical product, is validated by multiple cited industry analyses and exper

Sources cited: 13. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.